Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice

Biomedicine and Pharmacotherapy

Volumn 63, Issue 1, 2009, Pages 19-26

  Enomoto, Soichiro ^a   Sata, Masataka ^a   Fukuda, Daiju ^a   Nakamura, Kazuto ^a   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Apoptosis; Atherosclerosis; Inflammation; Plaque; Statin

Indexed keywords

APOLIPOPROTEIN E; CD31 ANTIGEN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN KINASE B; ROSUVASTATIN; SCARLET RED;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL DEATH; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STAINING;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL DEATH; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; FLUOROBENZENES; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SULFONAMIDES;

EID: 58049180113     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.11.002     Document Type: Article

References (37)

1. Ballantyne C.M. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 82 (1998) 3Q-12Q
2. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
3. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
4. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation 98 (1998) 839-844
5. Delanty N., and Vaughan C.J. Vascular effects of statins in stroke. Stroke 28 (1997) 2315-2320
6. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
7. Martinez-Gonzalez J., Raposo B., Rodriguez C., and Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 21 (2001) 804-809
8. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
9. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
10. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
11. Cheng J.W. Rosuvastatin in the management of hyperlipidemia. Clin Ther 26 (2004) 1368-1387
12. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 295 (2006) 1556-1565
13. Crouse III J.R., Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O'Leary D.H., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
14. Sata M., Kakoki M., Nagata D., Nishimatsu H., Suzuki E., Aoyagi T., et al. Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism. Hypertension 36 (2000) 83-88
15. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471
16. Sata M., Nishimatsu H., Osuga J., Tanaka K., Ishizaka N., Ishibashi S., et al. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43 (2004) 1214-1220
17. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103 (2001) 993-999
18. Kinlay S., Libby P., and Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 12 (2001) 383-389
19. Luscher T.F., and Barton M. Biology of the endothelium. Clin Cardiol 20 II (1997) 3-10
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340 (1999) 115-126
21. Ludmer P.L., Selwyn A.P., Shook T.L., Wayne R.R., Mudge G.H., Alexander R.W., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315 (1986) 1046-1051
22. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
23. Dupuis J., Tardif J.C., Cernacek P., and Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (1999) 3227-3233
24. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 279 (1998) 1643-1650
25. Sata M., Nishimatsu H., Suzuki E., Sugiura S., Yoshizumi M., Ouchi Y., et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J 15 (2001) 2530-2532
26. Masumoto A., Hirooka Y., Hironaga K., Eshima K., Setoguchi S., Egashira K., et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 88 (2001) 1291-1294
27. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
28. Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D.S., Yang S.X., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest 106 (2000) 15-24
29. Pelat M., Dessy C., Massion P., Desager J.P., Feron O., and Balligand J.L. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 107 (2003) 2480-2486
30. Jones S.P., Gibson M.F., Rimmer III D.M., Gibson T.M., Sharp B.R., and Lefer D.J. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
31. Dimmeler S., Haendeler J., Nehls M., and Zeiher A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med 185 (1997) 601-607
32. Shiojima I., and Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90 (2002) 1243-1250
33. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
34. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
35. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
36. Kleemann R., Princen H.M., Emeis J.J., Jukema J.W., Fontijn R.D., Horrevoets A.J., et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108 (2003) 1368-1374
37. Monetti M., Canavesi M., Camera M., Parente R., Paoletti R., Tremoli E., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 55 (2007) 441-449